FIELD: medicine.
SUBSTANCE: invention refers to application of vasopeptidase inhibitors for treatment and/or prevention of nephropathy in diabetics or nondiabetics as well as for treatment and/or prevention of insulin resistance or metabolic disorder associated with profound glycolysis end products.
EFFECT: offered compounds have higher therapeutic efficiency in prevention and treatment of diabetic nephropathy development and higher activity in treatment and prevention of insulin resistance.
4 cl, 7 ex, 15 tbl, 1 dwg
Authors
Dates
2008-10-20—Published
2003-06-13—Filed